Further clinical research is needed to determine contexts where GLP1R agonists may be repurposed for reducing risk of heart failure, particularly given the established effects of sodium glucose cotransporter 2 inhibitors for reducing progression of heart failure in patients with and without type 2 diabetes mellitus.14 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.